Abstract:Aims: To investigate the relationship between N-terminal pro-B-type natriuretic peptide (NT-proBNP), Glomerular Filtration Rate (GFR), and outcomes in patients hospitalized with acute heart failure (AHF). Methods: The trial was registered at http://www.chictr.org/cn/. (ChiCTR - ONC - 12001944). A total of 493 patients hospitalized for AHF in cardiology department of the First Affiliated Hospital of Nanjing Medical University from March 2012 to October 2016 were enrolled into registry. The end event was the occurrence of all-cause death within an 18-month follow-up. The data collected from the participants in admission were used to calculate the GFR by chronic kidney disease epidemiology collaboration equation (CKD-EPI) and performed the according statistical analysis. Results: There were 74 participants (13.8%) dropped out and 91 (21.7%) passed away within the 18-month follow up. Comparison of clinical indicators between survival and death group were analyzed for the long-term prognosis of patients with AHF. In the single factor analysis, both NT-proBNP and GFR were statistically significant (P < 0.001). Combined NT-proBNP and GFR in multi-factor COX regression analysis showed significant predictive value (P < 0.001). In receiver operator characteristics (ROC) analyses, the area under the curves (AUC) for NT-proBNP was 0.648 [95%CI: 0.598-0.695, P < 0.001] and for GFR was 0.677 [95%CI: 0.627-0.723, P < 0.001]. According to the Youden index, the best prediction point of NT-proBNP was 2,137 pg/ml and GFR was 61.7 ml/(min·1.73 m2). After using the Binary Logistic Regression to combine the two indicators, the AUC was 0.711, which was significantly compared to the AUC of either single factor. The sensitivity of the combined indicators were 0.535, the specificity were 0.853. According to the cut-off point, these two indexes were separated into four groups for further analysis by Kaplan-Meier survival curve comparison (log-rank test), which showed that patients in the group with higher NT-proBNP and lower GFR had the worst prognosis. Conclusions: In patients with NT-proBNP > 2,137 pg/ml and GFR < 61.7 ml/(min·1.73 m2), the risk of death was significantly higher. The combination of GFR and NT-proBNP improved the predictive value for the long-term prognosis of AHF patients.

N-terminal Pro-Brain Natriuretic Peptide in Predicting Early Clinical Response to Cardiac Resynchronization Therapy in Patients with Heart Failure

The change of plasma N-terminal brain natriuretic peptide(BNP) level in the heartt failure patients after cardiac resynchronization therapy

Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure.

Predictive Value of Clinical and Echocardiographic Parameters on Cardiac Resynchronization Therapy

The dynamic of serum N-terminal pro-brain natriuretic peptide and troponin T in pre- and post-cardiac resynchronization therapy

Potential Effect of B-type Natriuretic Peptides in Predicting Response Patients and Outcome of Cardiac Resynchronization Therapy

Predictors for Cardiac Resynchronization Therapy Response

[Factors Associated with the Efficacy of Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure].

Elevated N-terminal Pro C-type Natriuretic Peptide is Associated with Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement.

Long Term Prognostic Value of N-terminal Pro-Brain Natriuretic Peptide Level in Acute Coronary Syndrome

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients with Acute Heart Failure

Significance of NT-proBNP Level in Patients with Heart Failure after Interventional Treatment and Value Prediction on Myocardial Function

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

Prognostic value of N-terminal B-type natriuretic peptide in patients with chronic heart failure

N-terminal pro-Brain natriuretic peptide as a useful biomarker for monitoring prognosis in patients with cardiac valve replacement.

Serum Levels of N-terminal Pro-Brain Natriuretic Peptide and Matrix Metalloproteinase-9 in Patients with Chronic Heart Failure Before and after Cardiac Resynchronization Therapy

Prognostic Value of NT-proBNP in Patients With Successful PCI for ACS and Normal Left Ventricular Ejection Fraction

The role of NT-proB NP in high-risk cardiovascular patients for long-term prognosis

Plasma BNP Combined with NT-proBNP versus Routine Cardiac Function Parameters for Predicting Postoperative Prognosis in Patients with Heart Valve Replacement Surgery:a Comparative Study

The Effectiveness of NT-proBNP in Diagnosing Heart Failure

Clinical evaluation effect of brain natriuretic peptide in patients with heart failure